Karaciğer Metastazlarında Radyoterapinin Yeri
Özet
Karaciğer metastazları, kanser hastalarında mortalite ve morbiditenin en sık nedenleri arasında yer almakta ve en sık kolorektal karsinomlardan kaynaklanmaktadır. Standart tedavi küratif cerrahi rezeksiyon olsa da hastaların yalnızca %10-20'si rezeksiyona uygundur. Cerrahiye veya radyofrekans ablasyon (RFA) gibi lokal ablatif yöntemlere uygun olmayan inoperabl hastalarda, Stereotaktik Vücut Radyoterapisi (SBRT) yüksek lokal kontrol oranları ve azalmış toksisite profili ile etkili bir tedavi alternatifi olarak öne çıkmaktadır. Yapılan çok sayıda faz I/II çalışması ve birleştirilmiş analizler, SBRT'nin oligometastatik hastalarda yüksek tümör yanıtı sağladığını ve özellikle 3 cm'den küçük lezyonlarda biyolojik efektif doz artışıyla lokal kontrolün %90'ların üzerine çıkabildiğini göstermektedir. Geleneksel tüm karaciğer radyoterapisinde karaciğer toleransı 30 Gray ile sınırlıyken, modern SBRT teknikleri (solunum kontrolü, ileri planlama) çevre dokuları koruyarak hedef hacme yüksek dozların güvenle verilmesini mümkün kılmaktadır. Tedavinin en kritik doz sınırlayıcı yan etkisi, genellikle ilk 3 ayda halsizlik, asit ve karaciğer enzim yüksekliğiyle saptanan radyasyona bağlı karaciğer hastalığıdır (RILD); ancak bu risk, ışınlanan normal karaciğer hacmi azaltılarak minimize edilebilir. Sonuç olarak SBRT, karaciğer metastazlarının yönetiminde güvenli ve standart olma yolunda ilerleyen bir tedavi modalitesidir.
Liver metastases represent a leading cause of mortality and morbidity among cancer patients, originating most frequently from colorectal carcinomas. Although curative surgical resection remains the gold standard, only 10-20% of patients are eligible for surgery. For inoperable cases unsuitable for surgery or other local ablative methods like radiofrequency ablation (RFA), Stereotactic Body Radiotherapy (SBRT) has emerged as an effective therapeutic alternative with high local control rates and minimal toxicity. Numerous phase I/II trials and pooled analyses demonstrate that SBRT achieves substantial tumor response in oligometastatic patients; specifically, increasing the biological effective dose can elevate local control rates above 90% for lesions smaller than 3 cm. While traditional whole-liver radiotherapy is constrained by a liver tolerance threshold of 30 Gray, modern SBRT techniques (including respiratory gating and advanced treatment planning) enable the safe delivery of ablative doses by ensuring a sharp dose fall-off outside the target volume. The primary dose-limiting complication is radiation-induced liver disease (RILD), typically presenting within three months via fatigue, ascites, and elevated liver enzymes, though this risk decreases significantly with smaller irradiated normal liver volumes. Consequently, SBRT stands out as a safe, highly effective modality transforming the management of hepatic metastases.
Referanslar
Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin N Am. 2005 Mar;18(1):75–84, viii.
Grover A, Alexander HR. The past decade of experience with isolated hepatic perfusion. The Oncologist. 2004;9(6):653–64.
Mazzaglia PJ, Berber E, Siperstein AE. Radiofrequency thermal ablation of metastatic neuroendocrine tumors in the liver. Curr Treat Options Oncol. 2007 Aug;8(4):322–30.
Bojalian MO, Machado GR, Swensen R, Reeves ME. Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review. Gynecol Oncol. 2004 May;93(2):557–60.
Yoon SS, Tanabe KK. Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases. The Oncologist. 1999;4(3):197–208.
Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès J-P, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013 Sep;59(9):1384–92.
Abbas S, Lam V, Hollands M. Ten-Year Survival after Liver Resection for Colorectal Metastases: Systematic Review and Meta-Analysis. ISRN Oncol. 2011;2011:763245.
Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. The Oncologist. 2008 Oct;13(10):1063–73.
Gerda F, Csaba P, Zsuzsánna Z, Barbara M-B, Gábor S, Balázs M, et al. Májáttétes betegek sztereotaxiás ablatív sugárkezelésével (SABRT) elért első eredményeink. Magy Onkol. 2018;6.
Malik U, Mohiuddin M. External-beam radiotherapy in the management of liver metastases. Semin Oncol. 2002 Apr;29(2):196–201.
Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys. 1981 May;7(5):587–91.
Leibel SA, Pajak TF, Massullo V, Order SE, Komaki RU, Chang CH, et al. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1057–64.
Bydder S, Spry NA, Christie DRH, Roos D, Burmeister BH, Krawitz H, et al. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australas Radiol. 2003 Sep;47(3):284–8.
Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Apr 1;27(10):1585–91.
Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005 Oct;15(4):279–83.
Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2001 Jan 1;19(1):164–70.
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep 1;117(17):4060–9.
Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol Stockh Swed. 1995;34(6):861–70.
Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, et al. A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Ann Surg Oncol. 2016 Jan;23(1):218–24.
Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, Nowak PCJM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol Stockh Swed. 2006;45(7):831–7.
Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol Stockh Swed. 2006;45(7):823–30.
Wulf J, Hädinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2001 Dec;177(12):645–55.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Apr 1;27(10):1572–8.
Wada H, Takai Y, Nemoto K, Yamada S. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1114–20.
Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB. 2013 Nov;15(11):851–7.
McPartlin A, Swaminath A, Wang R, Pintilie M, Brierley J, Kim J, et al. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):388–95.
Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015 Mar;141(3):543–53.
Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1237–48.
Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):117–23.
Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Semin Radiat Oncol. 2001 Jul;11(3):240–6.
Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. RADIATION HEPATITIS. Am J Roentgenol Radium Ther Nucl Med. 1965 Jan;93:200–8.
